Ivana Jeziskova

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Journal: Leukemia
Published: September 08, 2025

Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.

Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.

Journal: Leukemia
Published: January 31, 2025

Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.

Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.

Journal: American journal of hematology
Published: October 29, 2024

Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.

Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.

Journal: Cancer medicine
Published: February 16, 2024

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.

Journal: American journal of hematology
Published: November 30, 2023

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.

Journal: Leukemia
Published: November 30, 2023

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.

Journal: Blood advances
Published: November 13, 2023

MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia.

MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia.

Journal: Clinical epigenetics
Published: September 18, 2023

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience.

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience.

Journal: Haematologica
Published: October 21, 2022

Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.

Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.

Journal: Leukemia & lymphoma
Published: September 01, 2022

Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.

Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.

Journal: Molecular biology reports
Published: February 03, 2022

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel.

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel.

Journal: Clinical epigenetics
Published: September 23, 2021
Showing 1-12 of 28

Last Updated: 09/26/2026